Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 9 of 18
Next
>>
>
201 to 225 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC38	Torin1	3	72	sigmoid	sigmoid	HCC38 Torin1 0 3 72	8	1.441	0.0231	-0.202	0.666	0.0412	-0.248	0.698	0.999	5.79e-10	NA	0.0787	0.266	0.572	0.0306	0.245	0.714	0.999	5.55e-10	NA
HCC38	Torin2	1	72	sigmoid	sigmoid	HCC38 Torin2 0 1 72	8	1.778	0.0133	-0.318	0.753	0.0337	-0.369	0.594	0.994	1.98e-07	NA	0.0264	0.148	0.459	0.0158	0.145	0.664	0.994	1.7e-07	NA
HCC38	Torin2	2	72	sigmoid	sigmoid	HCC38 Torin2 0 2 72	8	2.140	0.0146	-0.48	0.793	0.0654	-0.634	0.545	0.993	3.78e-07	NA	0.0176	0.056	0.391	0.015	0.0502	0.68	0.989	1.33e-06	NA
HCC38	Torin2	3	72	sigmoid	sigmoid	HCC38 Torin2 0 3 72	8	1.385	0.013	-0.624	0.855	0.0547	-0.706	0.615	0.996	8.13e-08	NA	0.0407	0.0986	0.484	0.0311	0.0829	0.669	0.997	3.31e-08	NA
HCC38	Trametinib	1	72	sigmoid	sigmoid	HCC38 trametinib 0 1 72	8	1.733	0.162	0.196	0.407	0.173	-0.0184	0.559	0.948	0.000139	NA	0.568	0.41	0.686	0.161	0.234	0.501	0.947	0.000151	NA
HCC38	Trametinib	2	72	sigmoid	sigmoid	HCC38 trametinib 0 2 72	8	2.133	0.219	0.267	0.389	0.222	-0.00324	0.424	0.987	2.39e-06	NA	0.391	0.377	0.644	0.127	0.183	0.404	0.988	1.91e-06	NA
HCC38	Trametinib	3	72	sigmoid	sigmoid	HCC38 trametinib 0 3 72	8	1.486	0.229	0.132	0.342	0.19	0.108	1.3	0.969	2.85e-05	NA	0.689	0.429	0.766	0.176	0.409	1.25	0.962	5.31e-05	NA
HCC38	WYE-125132	1	72	sigmoid	sigmoid	HCC38 WYE-132 0 1 72	8	1.708	0.0604	0.142	0.447	0.0481	0.134	1.36	0.997	3.43e-08	NA	0.115	0.384	0.669	0.0413	0.381	1.4	0.996	6.46e-08	NA
HCC38	WYE-125132	2	72	sigmoid	sigmoid	HCC38 WYE-132 0 2 72	8	2.143	0.0568	0.149	0.473	0.0413	0.124	0.896	0.998	9.66e-09	NA	0.078	0.305	0.587	0.0297	0.285	0.875	0.997	1.58e-08	NA
HCC38	WYE-125132	3	72	sigmoid	sigmoid	HCC38 WYE-132 0 3 72	8	1.449	0.0494	-0.0216	0.518	0.0504	-0.0117	1.18	0.998	9.69e-09	NA	0.128	0.355	0.662	0.0441	0.361	1.2	0.998	9.53e-09	NA
HCC38	XL147	1	72	flat	flat	HCC38 pilaralisib 0 1 72	8	1.752	Inf	0.949	0.0257	0.0	0.949	0.01	-0.0703	1.0	0.973	Inf	0.955	0.978	0.0	0.955	0.01	-0.0701	1.0	0.977
HCC38	XL147	2	72	flat	flat	HCC38 pilaralisib 0 2 72	8	2.194	Inf	0.938	0.0288	0.0	0.938	0.01	-0.0925	1.0	0.968	Inf	0.933	0.969	0.0	0.933	0.01	-0.0418	1.0	0.965
HCC38	XL147	3	72	sigmoid	sigmoid	HCC38 pilaralisib 0 3 72	8	1.420	Inf	0.909	0.0219	0.114	0.921	5.0	0.815	0.00631	NA	Inf	0.936	0.985	0.114	0.945	5.0	0.813	0.00654	NA
HCC38	ZSTK474	1	72	sigmoid	sigmoid	HCC38 ZSTK474 0 1 72	8	1.742	2.47	0.456	0.132	1.34	0.202	0.843	0.991	7.12e-07	NA	9.02	0.575	0.893	1.0	0.426	0.869	0.99	1.01e-06	NA
HCC38	ZSTK474	2	72	sigmoid	sigmoid	HCC38 ZSTK474 0 2 72	8	2.253	1.63	0.396	0.196	2.18	-0.0865	0.554	0.984	4.3e-06	NA	2.0	0.445	0.803	1.14	0.135	0.556	0.982	5.91e-06	NA
HCC38	ZSTK474	3	72	sigmoid	sigmoid	HCC38 ZSTK474 0 3 72	8	1.458	2.06	0.398	0.146	5.06	-0.41	0.665	0.989	1.23e-06	NA	6.44	0.593	0.898	3.35	0.179	0.678	0.988	1.64e-06	NA
HCC70	AS605240	1	72	sigmoid	sigmoid	HCC70 AS-605240 0 1 72	8	1.387	10.4	0.487	0.159	0.247	0.497	1.34	0.963	5.14e-05	NA	Inf	0.663	0.894	0.23	0.672	1.39	0.961	6.01e-05	NA
HCC70	AS605240	2	72	sigmoid	sigmoid	HCC70 AS-605240 0 2 72	8	1.771	6.13	0.558	0.126	1.21	0.339	0.698	0.981	7.24e-06	NA	785.0	0.643	0.894	0.946	0.496	0.708	0.978	1.04e-05	NA
HCC70	AS605240	3	72	sigmoid	sigmoid	HCC70 AS-605240 0 3 72	8	2.447	Inf	0.58	0.112	0.427	0.549	1.18	0.985	3.24e-06	NA	Inf	0.562	0.877	0.345	0.544	1.24	0.982	6.14e-06	NA
HCC70	AZD-6482	1	72	sigmoid	sigmoid	HCC70 AZD6482 0 1 72	8	1.368	0.0982	0.0128	0.462	0.205	-0.212	0.481	0.975	1.49e-05	NA	0.767	0.394	0.704	0.121	0.305	0.509	0.973	1.9e-05	NA
HCC70	AZD-6482	2	72	sigmoid	sigmoid	HCC70 AZD6482 0 2 72	8	1.772	0.267	0.256	0.366	0.237	0.0255	0.43	0.987	2.27e-06	NA	1.16	0.438	0.706	0.133	0.306	0.437	0.986	3.03e-06	NA
HCC70	AZD-6482	3	72	sigmoid	sigmoid	HCC70 AZD6482 0 3 72	8	2.532	1.43	0.435	0.247	0.421	0.226	0.492	0.983	4.63e-06	NA	1.13	0.431	0.729	0.208	0.286	0.5	0.982	6.2e-06	NA
HCC70	AZD8055	1	72	sigmoid	sigmoid	HCC70 AZD8055 0 1 72	8	1.339	0.0485	0.242	0.442	0.0243	0.26	1.06	0.976	1.32e-05	NA	Inf	0.529	0.721	0.0222	0.54	1.08	0.974	1.81e-05	NA
HCC70	AZD8055	2	72	sigmoid	sigmoid	HCC70 AZD8055 0 2 72	8	1.724	0.17	0.404	0.346	0.0331	0.385	0.897	0.996	7.36e-08	NA	Inf	0.543	0.728	0.0284	0.531	0.905	0.996	6.22e-08	NA
HCC70	AZD8055	3	72	sigmoid	sigmoid	HCC70 AZD8055 0 3 72	8	2.442	Inf	0.571	0.287	0.0133	0.574	1.17	0.98	8.55e-06	NA	Inf	0.554	0.694	0.0116	0.556	1.17	0.974	1.69e-05	NA

|<
<<
Previous
Page 9 of 18
Next
>>
>
201 to 225 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)